Science & Enterprise subscription

Follow us on Twitter

  • Regulatory review of a drug to prevent allergic reactions to peanuts appears to be delayed by the shutdown of some… https://t.co/mSAKgI1Dry
    about 6 hours ago
  • New post on Science and Enterprise: Shutdown Delays FDA Peanut Allergy Drug Review https://t.co/vvspUdBnOM #Science #Business
    about 6 hours ago
  • Customized implants, produced on a 3-D printer and seeded with stem cells, are shown in tests with lab animals to… https://t.co/hc4xTlmSQq
    about 10 hours ago
  • New post on Science and Enterprise: 3-D Printed Implants Treat Spinal Cord Injury https://t.co/2ZiVpVvMIz #Science #Business
    about 10 hours ago
  • New contributed post on Science and Enterprise: https://t.co/z76z7xMWD3 Lighten The Load: Making Business Ownership Less Complex
    about 16 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Chip Device to Test Gut Infections on Space Station

Tissue on intestine chip

A device with human intestine tissue and cells will be launched into space to test effects of weightlessness on immune functions and bacterial infections in the gastrointestinal tract. . . . → Read More: Chip Device to Test Gut Infections on Space Station

Virtual Reality Illness Fix in Development

Man in virtual reality headset

A computer science and engineering team in Texas is developing a technical solution for virtual reality experiences that can make some users physically ill, with symptoms like seasickness. . . . → Read More: Virtual Reality Illness Fix in Development

Nanotech Gene Therapy Company Raises $8.5M in Seed Funds

Editing DNA

A start-up company developing nanoscale particles to deliver gene-editing enzymes, including those for Crispr, is raising $8.5 million in its seed funding round. . . . → Read More: Nanotech Gene Therapy Company Raises $8.5M in Seed Funds

RNA Biotech Raises $604M in IPO

NASDAQ share price display

Moderna Therapeutics, a biotechnology enterprise developing therapies with synthetic RNA, issued its initial public stock offering, or IPO, on Thursday, raising more than $604 million. . . . → Read More: RNA Biotech Raises $604M in IPO

Janssen Licensing Cancer Antibodies in $1.8B Deal

Llama

An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal

Project to Catalog Precision Lung Cancer Immunotherapies

Lung cancer development

A new research initiative in the U.K. is collecting and mapping precise combinations of therapies that invoke the immune system to treat lung cancer. . . . → Read More: Project to Catalog Precision Lung Cancer Immunotherapies

Personalized Computer Models Developed for Heart Disease

Heart check

Researchers in the U.K. are developing computer models of heart functions that enable physicians to simulate recommended treatments for individual patients to gauge and optimize their outcomes. . . . → Read More: Personalized Computer Models Developed for Heart Disease

3-D Printed Scaffolds with Stem Cells, Sensors Studied to Repair Bones

3-D printed bone scaffold

A bioengineering lab at University of Arizona is researching new techniques with three-dimensional printing, stem cells, and sensors to repair severe bone fractures. . . . → Read More: 3-D Printed Scaffolds with Stem Cells, Sensors Studied to Repair Bones

NSF Supports Expanding Lab-On-Chip Integration, Manufacturing Center

Cadmim leadership

A new federal grant supports expansion of a research and development center developing techniques to make the manufacture and integration of microfluidic, or lab-on-a-chip, devices easier and less expensive. . . . → Read More: NSF Supports Expanding Lab-On-Chip Integration, Manufacturing Center

RNA Therapeutics Company Raises $30M in First Venture Round

Kevin Weeks

A company spun-off from a university biochemistry lab is raising $30 million to fund discovery of treatments targeting RNA, genetic material instructing protein production in cells. . . . → Read More: RNA Therapeutics Company Raises $30M in First Venture Round